business, technology
Moderna Shares Slide Despite Cancer Vaccine Cutting Melanoma Risk by 42%
Moderna shares extend losses after an 18% plunge despite positive Phase 3 melanoma vaccine results showing a 42% reduction in recurrence or death risk.
Moderna shares extend losses after an 18% plunge despite positive Phase 3 melanoma vaccine results showing a 42% reduction in recurrence or death risk.
This is a news summary.
AuthorityDock provides the headline and summary for discovery. The original publisher remains the source for the complete report.
Read Original Story ↗